HRP20190108T1 - Kimerni proteini na bazi hpv/cyaa i njihova upotreba u izazivanju imunosnih odgovora protiv infekcije hpv-om i poremećaja izazvanih hpv-om - Google Patents

Kimerni proteini na bazi hpv/cyaa i njihova upotreba u izazivanju imunosnih odgovora protiv infekcije hpv-om i poremećaja izazvanih hpv-om

Info

Publication number
HRP20190108T1
HRP20190108T1 HRP20190108TT HRP20190108T HRP20190108T1 HR P20190108 T1 HRP20190108 T1 HR P20190108T1 HR P20190108T T HRP20190108T T HR P20190108TT HR P20190108 T HRP20190108 T HR P20190108T HR P20190108 T1 HRP20190108 T1 HR P20190108T1
Authority
HR
Croatia
Prior art keywords
hpv
cyaa
immune responses
chimeric proteins
responses against
Prior art date
Application number
HRP20190108TT
Other languages
English (en)
Croatian (hr)
Inventor
Yolande Misseri
Philippe Bridonneau
Anne Goubier
Original Assignee
Genkyotex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genkyotex filed Critical Genkyotex
Publication of HRP20190108T1 publication Critical patent/HRP20190108T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01001—Aodenylate cyclase (4.6.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20190108TT 2012-07-23 2013-07-23 Kimerni proteini na bazi hpv/cyaa i njihova upotreba u izazivanju imunosnih odgovora protiv infekcije hpv-om i poremećaja izazvanih hpv-om HRP20190108T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305898.4A EP2689786A1 (en) 2012-07-23 2012-07-23 HPV/CYAA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders
EP13739725.3A EP2874657B1 (en) 2012-07-23 2013-07-23 Hpv/cyaa-based chimeric proteins and their uses in the induction of immune responses against hpv infection and hpv-induced disorders
PCT/EP2013/065549 WO2014016312A1 (en) 2012-07-23 2013-07-23 Hpv/cyaa-based chimeric proteins and their uses in the induction of immune responses against hpv infection and hpv-induced disorders

Publications (1)

Publication Number Publication Date
HRP20190108T1 true HRP20190108T1 (hr) 2019-03-22

Family

ID=48832935

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190108TT HRP20190108T1 (hr) 2012-07-23 2013-07-23 Kimerni proteini na bazi hpv/cyaa i njihova upotreba u izazivanju imunosnih odgovora protiv infekcije hpv-om i poremećaja izazvanih hpv-om

Country Status (21)

Country Link
US (1) US9827302B2 (enExample)
EP (2) EP2689786A1 (enExample)
JP (1) JP6466328B2 (enExample)
KR (1) KR20150031487A (enExample)
CN (1) CN104736173B (enExample)
AU (1) AU2013295047B2 (enExample)
CA (1) CA2879999A1 (enExample)
DK (1) DK2874657T3 (enExample)
ES (1) ES2712647T3 (enExample)
HR (1) HRP20190108T1 (enExample)
HU (1) HUE042808T2 (enExample)
LT (1) LT2874657T (enExample)
MX (1) MX2015001021A (enExample)
PL (1) PL2874657T3 (enExample)
PT (1) PT2874657T (enExample)
RS (1) RS58313B1 (enExample)
RU (1) RU2015100212A (enExample)
SI (1) SI2874657T1 (enExample)
SM (1) SMT201900057T1 (enExample)
TR (1) TR201900695T4 (enExample)
WO (1) WO2014016312A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2690172A1 (en) * 2012-07-23 2014-01-29 Genticel CYAA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses
EP3037103A1 (en) * 2014-12-23 2016-06-29 Genticel Immunotherapeutic vaccine comprising E7 proteins of HPV16 and HPV18 fused with CyaA, for use in subjects infected with HPV
EP3323424A1 (en) * 2016-11-17 2018-05-23 Cyanimal IP Cyaa polypeptides as immune enhancer
CA3109889A1 (en) * 2018-08-23 2020-02-27 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01209817A (ja) 1988-02-17 1989-08-23 Yamaha Corp 浮動少数点形ディジタル・アナログ変換器
PT1188446E (pt) 2000-09-15 2009-11-10 Pasteur Institut Vectores proteinácios para a distribuição da molécula a células que expressam cd11b
EP1489092A1 (en) 2003-06-18 2004-12-22 Institut Pasteur Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
PL1576967T3 (pl) * 2004-03-18 2008-03-31 Pasteur Institut Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne
US8183007B2 (en) 2008-07-22 2012-05-22 Promega Corporation ADP detection based methods using adenylate cyclase and bioluminescence
EP2478915A1 (en) * 2011-01-24 2012-07-25 Genticel CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses

Also Published As

Publication number Publication date
EP2874657B1 (en) 2018-10-17
RU2015100212A (ru) 2016-09-10
CA2879999A1 (en) 2014-01-30
JP2015524420A (ja) 2015-08-24
EP2689786A1 (en) 2014-01-29
JP6466328B2 (ja) 2019-02-13
CN104736173B (zh) 2019-02-05
EP2874657A1 (en) 2015-05-27
PL2874657T3 (pl) 2019-05-31
PT2874657T (pt) 2019-02-18
ES2712647T3 (es) 2019-05-14
DK2874657T3 (en) 2019-02-11
TR201900695T4 (en) 2019-03-21
US9827302B2 (en) 2017-11-28
KR20150031487A (ko) 2015-03-24
SI2874657T1 (sl) 2019-03-29
RS58313B1 (sr) 2019-03-29
LT2874657T (lt) 2019-02-25
HUE042808T2 (hu) 2019-07-29
HK1208822A1 (en) 2016-03-18
CN104736173A (zh) 2015-06-24
SMT201900057T1 (it) 2019-02-28
US20150250867A1 (en) 2015-09-10
MX2015001021A (es) 2015-08-05
WO2014016312A1 (en) 2014-01-30
AU2013295047A1 (en) 2015-02-05
AU2013295047B2 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
IL286784A (en) Compositions of protein and antibody
CL2014003605A1 (es) Proteínas de fusión de interleuquina-10 y usos de las mismas
HUE054437T2 (hu) Anti-CGRP készítmények és alkalmazásuk
BR112013021524A2 (pt) micro-organismos recombinantes e usos dos mesmos
HRP20181343T1 (hr) Postupci i pripravci za induciranje imunosnog odgovora na egfrviii
BR112015001211A2 (pt) novos ácidos 5-aminotetra-hidroquinolina-2-carboxílicos e sua utilização
EP2858663A4 (en) CHIMERIC FIBROBLAST GROWTH FACTOR 21 PROTEINS AND METHOD OF USE
IL238095B (en) Proteolytic inactivation of selected proteins in bacterial extraction to improve expression
DK2903600T3 (da) Virusholdig formulering og anvendelse deraf
DK3088353T3 (da) Bilirubinpartikler og deres fremstilling til anvendelse i terapi
EP2701705A4 (en) SYNTHETIC TOLEROGENIC NANOTRÄGER FOR REDUCING IMMUNE RESPONSES TO THERAPEUTIC PROTEINS
IL236920B (en) Ophthalmic compositions and their use for treatment of eye diseases and disorders in animals
HRP20182194T1 (hr) Onkolitički herpes simpleks virus i njegova terapeutska uporaba
DK2970398T3 (da) Præfusions-rsv-f-proteiner og anvendelse deraf
IL235512B (en) Phenylbenzamide derivatives for use in treating diseases mediated by aquaporin
HRP20190109T1 (hr) Ljudska antitijela na gfr 3 i načini za njihovu primjenu
PL2928905T3 (pl) Sposób oczyszczania białek terapeutycznych
PL2888593T3 (pl) Przeciwciała przeciwko rysperydonowi i ich zastosowanie
BR112013018742A2 (pt) cya-transportador de polipeptídeo(s) e use para induzir tanto as terapias e resposta imunitária profilática
HUE050438T2 (hu) Rekombináns fehérjék és terápiás alkalmazásuk
DK2869845T3 (da) Dimert protein med tredobbelte mutationer
DK3173102T3 (da) FGFR-FC-fusionsprotein og anvendelse deraf
BR112014015468A2 (pt) produto absorvente descartável com regiões laterais ligadas e métodos relacionados
GB2506939B (en) Improvements in and relating to ultrasonic cleaning
HUE042808T2 (hu) HPV/CYAA alapú kiméra fehérjék és alkalmazásuk a HPV fertõzések és a HPV indukálta betegségek elleni immunreakciók kiváltására